Letter to the Editor: Chronic Hepatitis B and Nonalcoholic Steatohepatitis: Is “Fat” All Bad?
Jie Li, Ramsey C. Cheung, Mindie H. Nguyen – 8 October 2019
Jie Li, Ramsey C. Cheung, Mindie H. Nguyen – 8 October 2019
8 October 2019
8 October 2019
8 October 2019
Hannah S. J. Choi, Willem P. Brouwer, Bettina E. Hansen, Harry L. A. Janssen, Keyur Patel – 8 October 2019
8 October 2019
Lars Asphaug, Maja Thiele, Aleksander Krag, Hans Olav Melberg – 8 October 2019
8 October 2019
Ranad Shaheen, Saud Alsahli, Nour Ewida, Fatema Alzahrani, Hanan E. Shamseldin, Nisha Patel, Awad Al Qahtani, Homoud Alhebbi, Amal Alhashem, Tarfa Al‐Sheddi, Rana Alomar, Eman Alobeid, Mohamed Abouelhoda, Dorota Monies, Abdulrahman Al‐Hussaini, Muneerah A. Alzouman, Mohammad Shagrani, Eissa Faqeih, Fowzan S. Alkuraya – 8 October 2019
Wei Zhang, Rui Huang, Yi Wang, Huiying Rao, Lai Wei, Grace L. Su, Anna S. Lok – 7 October 2019 – Several drugs in development for nonalcoholic fatty liver disease (NAFLD) aim to decrease the amount of fat in the liver. We compared quantity and quality of fat in subcutaneous, visceral and muscle compartments, liver fibrosis, and prevalence of metabolic abnormalities between Chinese patients with moderate/severe hepatic steatosis versus those with mild hepatic steatosis. NAFLD patients were prospectively recruited from Peking University People's Hospital in Beijing, China.